The global atenolol market size is estimated to reach ~USD 28 Billion by the end of 2035 by growing at a CAGR of ~5% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of atenolol was ~USD 11 Billion. The growth of the market can be attributed to the worldwide expanding ratio of hypertension among people, coupled with the surging awareness regarding the concerned complexities of hypertension. As per the World Health Organization (WHO) data, an estimated 1.28 billion persons aged 30-79 years have hypertension across the globe, with the majority two-thirds residing in low- and middle-income nations. Further, the dynamically growing demand for antihypertensive drugs throughout the world is also projected to skyrocket the growth of the global atenolol market over the forecast period.
In addition to these, factors that are believed to fuel the market growth of atenolol include the significant rise in the aged population throughout the world, as aged people are more prone to have disorders comprising hypertension, cardiac diseases, diabetes, and so on. As stated by the World Health Organization, the global population of persons aged 60 and above is projected to surge from 1 billion in 2020 to 1.4 billion by 2030. Moreover, the global population of people aged 60 and above is expected to augment to 2.1 billion by 2050. Further, poor lifestyle along with poor dietary habits among people is also estimated to fuel the market growth in the coming years.
Base Year |
2022 |
Forecast Year |
2023-2035 |
CAGR |
~5% |
Base Year Market Size (2022) |
~ USD 11 Billion |
Forecast Year Market Size (2035) |
~ USD 28 Billion |
Regional Scope |
|
Growth Drivers
Challenges
The global atenolol market is segmented and analyzed for demand and supply by application into hypertension, angina, arrhythmia, and others. Out of these four types of segments, the hypertension segment is estimated to gain the largest market share of about ~55% in the year 2035. The growth of the segment can be attributed to the increasing prevalence of hypertension throughout the world, coupled with the expanding demand and consumption of antihypertensive drugs across the globe. For instance, the worldwide revenue of antihypertensive drugs is anticipated to boost by around USD 24 billion by the end of 2023. In addition to this, the rising awareness in people regarding hypertension is also estimated to fuel the segment growth in the coming years.
The global atenolol market is also segmented and analyzed for demand and supply by distribution channel into hospital pharmacies, drug stores, online pharmacies, and others. Amongst these four segments, the hospital pharmacies segment is expected to garner a significant share of around ~49% in the year 2035. The growth of the segment can be attributed to the rising patient pool of hypertension, arrhythmia, angina, and so on in hospitals to get better treatment, coupled with the surging ratio of hospitals throughout the world. In addition to this, the rise in cardiovascular disorder is also anticipated to accelerate segment growth in the coming years. On the other hand, the online pharmacies segment is projected to witness an impressive CAGR during the forecast period on the back of the rising awareness of these online platforms amongst users worldwide. In addition to this, the expanding penetration of the internet throughout the world is another major factor estimated to drive segment growth across the globe in the coming years.
Our in-depth analysis of the global atenolol market includes the following segments:
By Form |
|
By Dosage Type |
|
By Application |
|
By Distribution Channel |
|
The market share of atenolol in North America, amongst the market in all the other regions, is projected to be the largest with a share of about ~40% by the end of 2035. The growth of the market can be attributed majorly to the increasing prevalence of cardiac diseases, along with the rising frequency of hypertension in the region. For instance, approximately 1 in every 18 people, or 5% of the U.S. population has arrhythmia. Furthermore, as per the statistics by the Centers for Disease Control and Prevention, in the U.S., 116 million individuals have hypertension, and in 2019, 0.5 million deaths were caused directly or indirectly by hypertension. In addition to this, the increasing availability of advanced treatment and medications, followed by the surge in healthcare expenditure is also projected to drive the growth of the atenolol market further during the projected time frame in the region.
The Asia Pacific atenolol market is estimated to be the second largest, registering a share of about ~28% by the end of 2035. The growth of the market can be attributed majorly to the rising burden of hypertension, coupled with the surge in population, and changing lifestyle of people in the region. Besides this, the growing awareness in people regarding the use of hypertension drugs is also a significant factor anticipated to drive market growth in the region during the forecast period. In addition to this, an increase in inappropriate diet habits, coupled with the surge in fast food consumption is also estimated to drive market growth in the APAC region during the forecast period.
Further, the market in Europe, amongst the market in all the other regions, is projected to hold a noteworthy share of about ~17% by the end of 2035. The growth of the market can be attributed majorly, as the region has witnessed a sharp hike in the cases of cardiovascular diseases. For instance, every year, more than 1.6 million deaths in the European Union and 4 million deaths in Europe are attributed to cardiovascular diseases. Moreover, efficient and inexpensive healthcare facilities in European countries are estimated to support the growth of the market. In addition to this, the surge in the life science sector is also estimated to drive the growth of the atenolol market in the European region.
Unichem Laboratories Limited obtained ANDA authorization from the United States Food and Drug Administration (USFDA) for its Atenolol and Chlorthalidone Tablets, USP 50 mg/25 mg and 100 mg/25 mg to be sold as a generic version of Alvogen Malta Operations Ltd's TENORETIC (atenolol and chlorthalidone) Tablets.
AstraZeneca PLC has approved the sale of the worldwide commercial rights Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril), and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma. This deal has eliminated the already sold rights in the United States and India, as well as the rights in Japan, which will be kept by AstraZeneca.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: Growing prevalence of angina experiences, expansion in sedentary lifestyle, and increasing prevalence of arrhythmia are the major factors driving the market growth.
Ans: The market size of atenolol is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2023 – 2035.
Ans: Associated side effects of atenolol, availability of diuretics and other drugs, and risk of interaction with other drugs are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are Intas Pharmaceuticals Limited, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Bio-Rad Laboratories, Inc., Sysmex Corporation, Ipca Laboratories Limited, and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by form, dosage type, application, distribution channel, and by region.
Ans: The hypertension segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)